AI assistant
Cartesian Therapeutics, Inc. — Director's Dealing 2024
Jan 4, 2024
33483_dirs_2024-01-04_d47c74fe-fd1f-45cd-ae64-d377e53fedf0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2024-01-02
Reporting Person: Davis Blaine (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-02 | Common Stock | A | 2424000 | — | Acquired | 2424000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-02 | Employee Stock Option (right to buy) | $0.6552 | A | 3110000 | Acquired | 2034-01-01 | Common Stock (3110000) | Direct |
Footnotes
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028.
F2: This option vests as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028.